Vol 92, No 2 (2016)

The examination and treatment of 48 patients with circumscribed scleroderma were conducted. Two groups of these patients were formed with method of adaptive randomization. In the control group complex treatment underwent according to the standards in this nosology. In the study one, we conducted ultratonotherapy. The course of treatment was 21 days in both groups. Treatment results were evaluated in accordance with the dynamics of cutaneous pathological process and microcirculation in the area of lesions. In the process of treatment positive clinical dynamics appeared in the study group earlier and were accompanied by increased blood flow. The results indicate that ultrasonotherapy increases the efficiency and reduces the treatment time of patients with circuscrimbed scleroderma.

The article discusses key aspects of the pathogenesis of atopic dermatitis and issues of the selection of pathogenetically substantiated therapy methods. The authors provide data on the efficient use of basic drugs used to treat dermatosis in children - topical glucocorticosteroids and calcineurin inhibitors. The authors also describe a current algorithm for using topical calcineurin inhibitors during the period of an exacerbation of atopic dermatitis and to prevent relapses.

A case study of nodular mastocytosis is described. Tacrolimus was used to treat skin manifestations of mastocytosis.

В обзоре обобщены и систематизированы имеющиеся международные данные по патогенезу, клиническим проявлениям и текущим рекомендациям по тактике ведения пациентов с розацеа.

Most of the developed countries as well as Russian Federation have a dynamically developing quality assurance system for testing the quality of laboratory tests and safety of perfumery and cosmetic products entering the market comprising a regulatory and legal framework, physical infrastructure and appropriate methodical basis and staff. At the same time, it is necessary to develop alternative test methods adjusted to perfumery and cosmetic products on a regular basis. In addition, it is necessary to optimize methods for ensuring standard sample preparation conditions in response to new forms of cosmetic products when determining microbiological, physical, chemical and toxicological characteristics, and more accurate observation methods for clinical and laboratory indices to be approved by supervising authorities.

Goal of the study. To study particular features of the immune status in microbial eczema and erysipelas patients in the process of a complex immune modulating therapy with Xymedone®. Materials and methods. the study involved 45 microbial eczema patients and 31 patients with a combined form of microbial eczema and erysipelas (the study group) and healthy subjects (60 and 50 subjects). All of the subjects underwent immunology examinations of their cell and humoral immunity prior to and after the pathogenetic treatment with Xymedone®. The traditional therapy of a combined course of microbial eczema and erysipelas comprised the following basic treatment: third-generation cephalosporins (ceftriaxone): 1.0 g a day for 10 days; second-generation antihistamine drugs (peroral loratadine 10 mg once a day for 10 days) and ascorbic acid 0.5 g a day for 14 days. topical treatment comprised antiseptic agents (furacilin solution 1:1000) at the acute stage, emulsions and creams (depending on the disease stage): topical mometasone furoate 0.1% twice a day for 14 days. The patients receiving Xymedone were treated in the dose of 0.25 g, one pill tree times a day for 14 days. The patients underwent an immunology study using the Sysmex Corporation XT2000 automated analyzer at the CityLab laboratory centers in the city of Kazan. Key findings. Prior to the pathogenic therapy, a high level of CD4 (T helpers) and reduced level of the immunoregulatory index (T helpers to T suppressors ratio) (IRI) was revealed in the microbial eczema patients. Ig А and Ig G concentrations were reliably increased. According to a study of immunology indices, the pathogenic therapy using Xymedone® normalized the number of peripheral blood leucocytes and reliably increased the IRI (p < 0.001) in 45 microbial eczema patients. Prior to the pathogenic therapy, a reduced level of CD3 and CD4 cells was revealed in patients with a combined form of microbial eczema and erysipelas; the levels of CD8 and NK cells (CD16) were also reduced. Ig А, Ig M and IgG concentrations were reliably reduced. According to a study of immunology indices, the pathogenic therapy using Xymedone® increased the concentration of CD3 and CD4 cells. Conclusion. Xymedone®, an immune modulating drug, administered as a part of a combination therapy of microbial eczema patients and patients with a combined form of microbial eczema and erysipelas is a form of supplementary pathogenic I therapy; the treatment improved the cellular and humoral immunity indices.

Introduction & objectives: The purpose of this study was to demonstrate the efficacy comparability of 1% NH lotion vs. of 1% NH cream (exoderil, Sandoz) in the treatment of pityriasis versicolor. Material & methods. 71 patients with pityriasis versicolor were randomly allocated either to receive NH lotion once daily (NH lotion group (п = 35, 38.6 years (95% CI [33,7, 43.5]) or NH cream once daily (NH cream group (п = 36, 40.8 years (95% CI [36,6, 45.0]) for 14 days. Mycological evaluations (microscopy and culture) were performed at weeks 2 and 3, inflammation symptoms evaluations were scored at day 3, weeks 2 and 3 after start of the therapy. Overall cure rates assessment included results of mycological, clinical outcomes and safety evaluation. Results. There was no difference between groups in mycological cure rates (94% vs 92%) and inflammation regression (97% vs 97%). Overall cure rate was 91% and 92% of patients in NH lotion and NH cream groups respectively (p = 0,97). Conclusion. 1% NH lotion and 1% NH cream are effective in the treatment of pityriasis versicolor.

Urgency. Acne is a prevalent polymorphous multifactorial inflammatory disease with various clinical forms ranging from the mildest ones (comedonal) to the most severe forms such as phlegmonous, indurative and cystic acne. According to epidemiology studies, the acne incidence rate in general population varies from 85% to 93%; moreover, there is a trend towards the growth in the incidence rate of postpubertal and persistent acne in adults. Acne treatment methods depend on the adequate clinical assessment of the disease severity, character of eruptions, skin type, any concomitant pathologies and patient’s age. Topical therapy is administered to all patients regardless of the disease severity and forms a mandatory part of the therapeutic complex treatment of acne patients. Despite the range of available drugs and treatment methods, researchers keep searching for new drugs and treatment methods for treating acne. Combination acne therapies enjoy keen interest in the world for reasons such as stable treatment results and improved compliance. It is essential that the administration of a combination therapy came along with drugs having a complimentary mechanism of action. Drug combinations have an effect on a large number of pathogenetic factors resulting in acne (excessive follicular hyperkeratosis, propagation of P. аспвв, inflammation). Goal. The goal of this article is a review of literature sources on current aspects of acne topical therapy and examining results of studies of a combination therapy, azelaic acid and clindamycin. Study materials and methods. The project was carried out at the GBOU VPO Kursk State Medical University, Ministry of Health of the Russian Federation. Major results. Both Russian and foreign authors use combination therapies with topical administration of azelaic acid and clindamycin on a broad scale. According to a study conducted in Russia, azelaic acid is a good combination substance for administration with both topical antibiotics (the antibiotic is to be applied to pustules once a day) and adapalene. According to the clinical study results, 15% azelaic acid (Azelic gel) as a part of a combination topical therapy reduces adverse effects observed in the course of a monotherapy with topical retinoids and improves the therapeutic efficacy when combined with antibacterial drugs. Conclusion. The practical experience and different variants of a combination therapy with 15% azelaic acid (Azelic gel) and 1% clindamycin gel (Clindovit) provide dermatologists with an opportunity to treat acne in different groups of patients on an everyday basis with increased efficacy achieving a longer remission of the inflammatory process.